13 August 2018
Visiongain has launched a new pharma report Global Medical Marijuana Market 2017-2027: Chronic Pain, Arthritis, Migraine, Cancer, National Markets, Patent Analysis, Leading Companies
Scientific studies of the extract of marijuana, called cannabinoids, have led to two FDA-approved medications that contain cannabinoid chemicals in pill form. Currently, the two main extract from the marijuana plant that are being used for medical treatments are THC and CBD. THC increases appetite and reduces nausea. THC also decrease pain, inflammation, and muscle control problems. CBD is useful in reducing pain and inflammation, controlling epileptic seizures, muscle spasms caused by multiple sclerosis, nausea, poor appetite, weight loss, crohn’s diseases and possibly treating mental illness and addictions.
The lead analyst of the report commented “Medical Marijuana is one the most promising method to treat various kinds of cancer. Moreover, scientists are doing constant research to make medical marijuana more effective. Hence, increasing research in the improvement of medical marijuana and constant development to find new treatment of cancer is one of the main factors driving the growth of this market.
The growing number of states legalizing medical marijuana and increasing demand for cannabis in medical applications are some of the pivotal factors that are expected to propel the demand for medical marijuana over the coming years.”
Leading companies featured in the report include Cara Therapeutics, Inc., Cannabis Sativa, Inc., CannaGrow Holdings, Inc., Aphios Corporation, United Cannabis Corporation, Growblox Sciences, Inc., GreenGro Technologies, Inc., GW Pharmaceutical, PLC., International Consolidated Companies, Inc., Lexaria Biosciences Corp.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
11 January 2021
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.